Inotiv delivered a strong third quarter in fiscal 2025, with revenue increasing by 23.5% year-over-year to $130.7 million, primarily due to growth in NHP-related products and services within the RMS segment and increased toxicology and biotherapeutic services in the DSA segment. The company also significantly reduced its operating loss from $20.8 million in Q3 FY 2024 to $5.7 million in Q3 FY 2025, largely due to improved RMS operating income and the absence of a prior year charge related to a DOJ agreement.
Third quarter fiscal 2025 revenue increased by 23.5% to $130.7 million compared to $105.8 million in the prior year.
Operating loss significantly decreased to $5.7 million in Q3 FY 2025 from $20.8 million in Q3 FY 2024, primarily due to a turnaround in RMS operating income.
RMS revenue saw a substantial increase of $21.0 million, driven by NHP-related product and service revenue.
DSA net awards for Q3 FY 2025 increased by 25% year-over-year, indicating strong future growth potential.
The report does not provide explicit forward-looking financial guidance for specific metrics like revenue or EPS for future quarters or the full fiscal year. However, management commentary suggests continued focus on financial goals and operational improvements.